Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Non-Current Assets (2018 - 2025)

Summit Therapeutics (SMMT) has disclosed Non-Current Assets for 7 consecutive years, with $15.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Assets rose 21.5% year-over-year to $15.3 million, compared with a TTM value of $54.9 million through Sep 2025, up 4.9%, and an annual FY2024 reading of $11.8 million, down 10.78% over the prior year.
  • Non-Current Assets was $15.3 million for Q3 2025 at Summit Therapeutics, up from $14.8 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $26.5 million in Q3 2021 and bottomed at $6.9 million in Q1 2023.
  • Average Non-Current Assets over 5 years is $14.7 million, with a median of $13.5 million recorded in 2023.
  • The sharpest move saw Non-Current Assets crashed 59.68% in 2023, then skyrocketed 96.74% in 2024.
  • Year by year, Non-Current Assets stood at $16.1 million in 2021, then crashed by 53.58% to $7.5 million in 2022, then surged by 77.53% to $13.2 million in 2023, then decreased by 10.78% to $11.8 million in 2024, then increased by 29.24% to $15.3 million in 2025.
  • Business Quant data shows Non-Current Assets for SMMT at $15.3 million in Q3 2025, $14.8 million in Q2 2025, and $13.1 million in Q1 2025.